Determining the Risk Elevation After Maternity (DREAM)
研究概览
详细说明
Preeclampsia is a complication of pregnancy that happens in about 5-7% of all births. It is diagnosed when a mother has high blood pressure in pregnancy combined with protein in the urine which is sign that the kidneys are not functioning properly. When a mother has preeclampsia, the placenta makes abnormal amounts of several important proteins that damage the lining of the mother's blood vessels. The blood vessel damage that occurs places women at up to 10 times higher risk of having a heart attack or stroke at a younger age than women who did not have preeclampsia. It usually takes between 8 and 15 years after preeclampsia is diagnosed for the first heart attack or stroke to occur.
Unfortunately, this blood vessel damage is usually silent, meaning that women and their doctors are not aware of it. This makes it hard to predict which women are at highest risk of a heart attack or stroke and therefore need extra medical care to prevent it. Abnormal levels of the placenta proteins in the blood (right after delivery and at three and six months after delivery) as well as abnormalities of the placenta itself may be the earliest way to predict which women with preeclampsia are at risk of premature heart disease or stroke.
The purpose of this study is to collect blood and placentas from women with preeclampsia and without preeclampsia to measure and compare the levels of proteins in the blood and find abnormalities of the placentas that are associated with preeclampsia. We will then see if these tests can predict which women will go on to develop high blood pressure and ultimately be at higher risk of premature heart attack or stroke after pregnancy.
研究类型
注册 (预期的)
联系人和位置
学习地点
-
-
Ontario
-
Ottawa、Ontario、加拿大、K1H 8L6
- The Ottawa Hospital, General Campus
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
Women with a pregnancy complicated by pre-eclampsia and women who are healthy and have had a normal singleton pregnancy(controls)
Exclusion Criteria:
Women with any of the following conditions will be excluded in both the control & preeclampsia groups:
- known kidney disease prior to pregnancy or laboratory evidence of proteinuria prior to pregnancy
- diabetes (Type I, Type II or Gestational Diabetes)
- known Cardiovascular Disease (myocardial infarction, angina, stroke, or transient ischemic attack
- multiple pregnancies (twins or more)
- who do not understand English or French will be excluded In addition to those listed above, for the control group, women must have no other major maternal pregnancy complications.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
---|---|
Preeclampsia- observational
45 women with preeclampsia
|
|
No preeclampsia- observational
10 women without preeclampsia
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
Persistence of high blood pressure (hypertension) and cardiovascular biomarkers in the blood at 6 months after a pregnancy with preeclampsia
大体时间:Six months after delivery
|
Six months after delivery
|
合作者和调查者
调查人员
- 首席研究员:Dr Laura Gaudet、Ottawa Hospital Research Institute
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.